Effects of Pubertal Blockade and Hormone Therapy on Cardiometabolic Risk Markers in Transgender Adolescents
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Change in Insulin sensitivity
研究概览
简要总结
This study will enroll female-to-male transgender youth who are and are not on a puberty blocker (gonadotropin-releasing hormone analogue) at baseline and 1 and 12 months after starting testosterone. The study will evaluate markers of cardiometabolic health including: insulin sensitivity, laboratory markers, vascular health, body composition, activity/fitness, mitochondrial function and the microbiome.
详细描述
There will be a total of 6 study visits: baseline A, baseline B, 1 month after starting testosterone (visit A and B) and 12 months after starting testosterone (visit A and B). No medications will be administered as a part of this study.
Visit A procedures: Physical Examination, Laboratory, and Oral Glucose Tolerance Test (OGTT) visit.
This will be conducted at Childrens Hospital Colorado (CHCO) Clinical & Translational Research Centers (CTRC) facilities. Physical examination will include vital signs, anthropometric measurements, and breast/pubic hair staging as applicable (some subjects may have already undergone mastectomy/chest masculinizing surgery) by the PI. Subjects will fast for 8 hours prior to blood draw. Fasting blood work will be obtained, followed by an oral glucose load (75g glucola). Blood glucose and insulin concentrations will be drawn at baseline and 30, 60, 90 and 120 minutes after glucola administration. Serum will be obtained at baseline and 2 hours post-OGTT and used for bile acid and lipid metabolomic profile. The following questionnaires will be administered: REDCap Health Questionnaire, PedsQLTM 4.0 generic core questionnaire, PROMIS Pediatric Anxiety Short Form, PROMIS Pediatric Depressive Symptoms Short Form, Insomnia Severity Index, Morningness and Eveningness Scale. Participants will be mailed or emailed the 3-day dietary log prior to the visit and return it at this visit. They will be given a stool microbiome collection kit and urine collection kit to return at visit B. The medical chart will be reviewed for relevant health information and medications.
Part B: Vascular Imaging, MR-based imaging and spectroscopy, Exercise Capacity and Dual-energy X-ray (DXA) visit.
This will be conducted at the University of Colorado Denver Energy Balance Core and UCD Brain Imaging Center. The participant will be fasting for a minimum of 4 hours prior to the beginning of the study visit. The investigators will perform the tests in the following order:
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 13 Years 至 16 Years（Child）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Identify as female-to-male
- •Age 13-16 years at the time of enrollment
- •If on a gonadotropin-releasing hormone analogue, > 6 months exposure
- •Plan to start testosterone clinically in < 6 months.
排除标准
- •Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures
- •Antipsychotic medication
- •Hypertension (resting BP ≥ 140/90 mm/Hg)
- •Weight > 400 lbs (DXA and MRI limit)
- •On estrogen and/or progesterone medications
结局指标
主要结局
Change in Insulin sensitivity
时间窗: Baseline and 12 months after initiation of testosterone.
Assessed by the Matsuda index, calculated from a 2-hour oral glucose tolerance test
Change in Vascular Health
时间窗: Baseline and 12 months after initiation of testosterone.
Brachial artery flow-mediated dilation
次要结局
- Change in Mitochondrial function(Baseline and 12 months after initiation of testosterone.)
- Change in Body composition(Baseline and 12 months after initiation of testosterone.)
- Change in VO2 peak(Baseline and 12 months after initiation of testosterone.)